Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

ABSTRACT:

Background

Standard care of adjuvant treatment for anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) is not yet well defined. The benefit of adjuvant chemotherapy and radiotherapy (RT), given as single modalities or sequentially, is still unclear. Furthermore, insight into the predictive and prognostic impact of various biomarkers is surging.

Objectives

To compare postoperative sequential RT and chemotherapy to RT alone in adults with newly diagnosed AO or mixed AOA. To evaluate the predictive and prognostic impact of the following biomarkers: codeletion of chromosomes 1p and 19q, O(6)-methylguanine-DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydrogenase (IDH)-1 and -2 mutations.

Search methods

We searched the Cochrane Ce

SUBMITTER: Lecavalier-Barsoum M 

PROVIDER: S-EPMC7388823 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature